外周血SCC、ProGRP、CA-125及CYFRA21-1在非小细胞肺癌诊断和预后评估中的临床价值  

Clinical Value of Peripheral Blood SCC,ProGRP,CA-125 and CYFRA21-1 in the Diagnosis and Prognostic Assessment of Non-small Cell Lung Cancer

作　　者：张梅芳 孙岚英 娄利梅 ZHANG Meifang;SUN Lanying;LOU Limei(Henan Invalids Hospital,Xinxiang,453000)

机构地区：[1]河南省荣军医院,453000

出　　处：《实用癌症杂志》2024年第1期56-60,共5页The Practical Journal of Cancer

摘　　要：目的探讨外周血鳞状上皮细胞癌抗原(SCC)、前胃泌素释放肽(ProGRP)、糖类癌抗原125(CA125)和细胞角蛋白19片段(CYFRA21-1)在非小细胞肺癌(NSCLC)诊断和预后评估中的临床价值。方法选取NSCLC患者(90例)作为肺癌组,另选取同期肺部良性病变作为良性组(82例)和体检健康者作为对照组(90例),统计3组外周血SCC、ProGRP、CA-125和CYFRA21-1水平,并采用ROC曲线分析SCC、ProGRP、CA-125和CYFRA21-1对NSCLC预后的预测效能,并采用Logistic回归分析NSCLC预后的影响因素。结果肺癌组血清SCC、ProGRP、CA-125和CYFRA21-1表达高于良性组和对照组(P<0.05);生存组血清SCC、ProGRP、CA-125和CYFRA21-1表达低于死亡组(P<0.05)。ROC曲线分析显示,SCC、ProGRP、CA-125、CYFRA21-1联合预测NSCLC预后的AUC为0.933,高于单一指标(P<0.05);采用二元Logistic回归分析,鳞癌、TNM分期T3~T4、淋巴结转移、SCC>1.57 ng/mL、ProGR P>73.04 pg/mL、CA125>29.53 U/mL、CYFRA21-1>3.00 ng/mL均为NSCLC预后的危险因素(P<0.05)。结论NSCLC患者外周血SCC、ProGRP、CA-125、CYFRA21-1表达升高,可用于患者预后评估。Objective To explore the clinical value of peripheral blood squamous cell carcinoma antigen(SCC),progastrin releasing peptide(ProGRP),carbohydrate cancer antigen 125(CA125)and cytokeratin fragment 19(CYFRA21-1)in the diagnosis and prognostic assessment of non-small cell lung cancer(NSCLC).Methods A total of 90 patients with NSCLC treated in the hospital were enrolled as lung cancer group,82 cases benign lung lesions were selected as the benign group and 90 healthy subjects who underwent physical examination during the same period were selected as the control group.The levels of peripheral blood SCC,ProGRP,CA-125 and CYFRA21-1 in three groups were statistically analyzed.Their diagnostic efficiency were analyzed by ROC curves,and the factors influencing the prognosis of NSCLC were analyzed by logistic regression.Results The expression levels of serum SCC,ProGRP,CA-125 and CYFRA21-1 in lung cancer group were higher than those in benign group and the control group(P<0.05).The expressions of serum SCC,ProGRP,CA-125 and CYFRA21-1 in survival group were lower than those in the death group(P<0.05).ROC curve analysis showed that the AUC of SCC combined with ProGRP,CA-125 and CYFRA21-1 for predicting the prognosis of NSCLC was 0.933,greater than that of single index(P<0.05).Binary logistic regression analysis,squamous carcinoma,TNM stage T3~T4,lymph node metastasis,SCC>1.57 ng/mL,ProGR P>73.04 pg/mL,CA-125>29.53 U/mL,and CYFRA21-1>3.00 ng/mL were all risk factors for NSCLC prognosis(P<0.05).Conclusion Peripheral blood SCC,ProGRP,CA-125,CYFRA21-1 expression is elevated in NSCLC patients and can be used for patient prognosis assessment.

关 键 词：非小细胞肺癌 鳞状上皮细胞癌抗原 前胃泌素释放肽 糖类癌抗原125 细胞角蛋白19片段 

分 类 号：R734.2[医药卫生—肿瘤]